血清NRCAM在小细胞肺癌诊断中的意义研究
该研究采用酶联免疫吸附试验检测80例小细胞肺癌(SCLC)、98例非小细胞肺癌(NSCLC)、73例肺结节(PN)患者及56例健康对照的血清NRCAM水平,并用化学发光免疫分析法检测NSE和ProGRP。结果显示SCLC患者NRCAM水平最高,NRCAM诊断SCLC特异性达94%,NRCAM联合NSE和ProGRP的AUC为0.94、灵敏度为91%。
要点
- SCLC患者血清NRCAM水平显著高于NSCLC、肺结节及健康对照。
- NRCAM诊断SCLC特异性最高达94%,与NSCLC鉴别时AUC为0.81、灵敏度74%。
- NRCAM联合NSE和ProGRP诊断SCLC的AUC达0.94、灵敏度91%。
核心结论
- 血清NRCAM对SCLC诊断具有重要潜力,可区分SCLC与NSCLC及肺结节。
- NRCAM、NSE和ProGRP联合检测可提高SCLC诊断性能,提供新的临床策略。
研究设计与样本
- 研究纳入80例SCLC患者、98例NSCLC患者、73例肺结节患者和56例健康对照。
- 采用酶联免疫吸附试验检测血清NRCAM,化学发光免疫分析法检测NSE和ProGRP。
主要发现
- 各组间血清NRCAM、NSE和ProGRP水平差异显著(P < 0.05),SCLC组最高。
- 血清NRCAM浓度与吸烟(r = 0.39)和淋巴结转移(r = 0.37)正相关(均P < 0.01)。
- NRCAM浓度与SCLC临床分期正相关,I-II期显著低于III-IV期(P < 0.01),非转移组显著低于转移组(P < 0.01)。
- 与NSCLC组比较,ProGRP诊断SCLC的AUC最大为0.86、灵敏度最高为76%;NRCAM特异性最高为94%。
- 与肺结节组比较,NRCAM诊断SCLC的AUC为0.81、灵敏度为74%;NSE特异性较高为93%。
临床怎么用
- 血清NRCAM可作为SCLC诊断的辅助标志物,尤其在与NSCLC和肺结节鉴别时。
- 联合检测NRCAM、NSE和ProGRP可能提高SCLC诊断的灵敏度和AUC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to investigate the clinical significance of serum neuronal cell adhesion molecule (NRCAM) in small cell lung cancer (SCLC) diagnosis. METHODS: Serum NRCAM levels were measured using enzyme-linked immunosorbent assay in 80 SCLC patients, 98 patients with non-small cell lung cancer (NSCLC), 73 patients with pulmonary nodules (PN) and 56 healthy controls. Neuron specific enolase (NSE) and progastrin-releasing peptide (ProGRP) expression were detected using chemiluminescence immunoassay. RESULTS: (1) Significant differences were detected in serum NRCAM, NSE and ProGRP levels among the groups (P < 0.05), with the highest levels observed in SCLC patients. (2) Correlation assessment revealed that serum NRCAM concentrations were positively correlated with smoking (r = 0.39) and lymph node metastasis (r = 0.37) (both P < 0.01). (3) NRCAM concentration was positively correlated with the clinical stage of SCLC, being significantly lower in stages I-II compared to stages III-IV (P < 0.01), and was remarkably lower in the non-metastatic group of SCLC relative to the metastatic group (P < 0.01). (4) Compared to the NSCLC group, ProGRP exhibited the largest area under the receiver operating characteristic curve (AUC) and the highest sensitivity for SCLC diagnosis, with values of 0.86 and 76 %, respectively. NRCAM had the highest specificity for SCLC diagnosis (94 %). Compared to the PN group, NRCAM exhibited a larger AUC (0.81) and higher sensitivity (74 %) for SCLC diagnosis. Conversely, NSE displayed a higher specificity for SCLC diagnosis (93 %). The combined diagnostic approach using NRCAM, NSE, and ProGRP yielded the largest AUC and the highest sensitivity, at 0.94 and 91 %, respectively. (5) Binary logistic regression analysis revealed that smoking and lymph node metastasis were potential risk factors influencing serum NRCAM levels. CONCLUSIONS: NRCAM possess significant potential for diagnosing SCLC and distinguishing SCLC from NSCLC and PN. Moreover, the combination detection of NRCAM, NSE, and ProGRP may enhance diagnostic performance, offering a novel clinical strategy for SCLC.
引用
- Chen Y, Han K, Wei L, et al. Investigating the diagnostic significance of serum NRCAM in small cell lung cancer. Clin Chim Acta. 2026. PMID: 41506357. doi:10.1016/j.cca.2025.120815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。